Do you want to read an article? Please log in or register.
Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety
Related content
Asthma
Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
Allergy Asthma Immunol Res.
Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N; China Omalizumab Study Group
doi: 10.4168/aair.2016.8.4.319.
Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
BMJ Open.
Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH, Hacking V, McLain-Smith S, Menzies-Gow A.
doi: 10.1136/bmjopen-2016-011857
RECOMMENDED
Asthma
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kucharczyk A, Więsik-Szewczyk E, Poznańska A, Jahnz-Różyk K
doi: 10.2147/JAA.S282203
RECOMMENDED
Asthma
Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Just J, Thonnelier C, Bourgoin-Heck M, Mala L, Molimard M, Humbert M, STELLAIR Investigators.
doi: 10.2147/JAA.S310888
Asthma
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
J Allergy Clin Immunol.
Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M7, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Rosén K, Trzaskoma B, Busse WW
doi: 10.1016/j.jaci.2017.03.002.
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
Asthma
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
Adv Ther.
Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A
doi: 10.1007/
COMMENTED
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
Thorax.
Vennera MDC, Sabadell C, Picado C; Spanish Omalizumab Registry
doi: 10.1136/thoraxjnl-2017-
RECOMMENDED
AsthmaFurther Publications
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M
doi: 10.1016/S2213-2600(21)00322-2